

[< Back](#)

Advertise

[American Journal of Reproductive Immunology / Volume 70, Issue 4 / p. 309-316](#)

Original Article

Human Papilloma Virus Vaccine and Primary Ovarian Failure: Another Facet of the Autoimmune/Inflammatory Syndrome Induced by Adjuvants

Serena Colafrancesco, Carlo Perricone, Lucija Tomljenovic, Yehuda Shoenfeld 

First published: 31 July 2013

<https://doi.org/10.1111/aji.12151>

Citations: 83

Abstract

Problem

Post-vaccination autoimmune phenomena are a major facet of the autoimmune/inflammatory syndrome induced by adjuvants (ASIA) and different vaccines, including HPV, have been identified as possible causes.

Method of study

The medical history of three young women who presented with secondary amenorrhea following HPV vaccination was collected. Data regarding type of vaccine, number of vaccination, personal, clinical and serological features, as well as response to treatments were analyzed.

Results

All three patients developed secondary amenorrhea following HPV vaccinations, which did not resolve upon treatment with hormone replacement therapies. In all three cases sexual development was normal and genetic screen revealed no pertinent abnormalities (i.e., Turner's syndrome, Fragile X test were all negative). Serological evaluations showed low levels of estradiol and increased FSH and LH and in two cases, specific auto-antibodies were detected (antiovarian and anti thyroid), suggesting that the HPV vaccine triggered an autoimmune response. Pelvic ultrasound did not reveal any abnormalities in any of the three cases. All three patients experienced a range of common non-specific

[< Back](#)

diagnosis of primary ovarian failure (POF) was determined which also fulfilled the required criteria for the ASIA syndrome.

Conclusion

We documented here the evidence of the potential of the HPV vaccine to trigger a life-disabling autoimmune condition. The increasing number of similar reports of post HPV vaccine-linked autoimmunity and the uncertainty of long-term clinical benefits of HPV vaccination are a matter of public health that warrants further rigorous inquiry.

References



1 Orbach H, Agmon-Levin N, Zandman-Goddard G: Vaccines and autoimmune diseases of the adult. *Discov Med* 2010; **9**: 90–97.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

2 Agmon-Levin N, Zafrir Y, Paz Z, Shilton T, Zandman-Goddard G, Shoenfeld Y: Ten cases of systemic lupus erythematosus related to hepatitis B vaccine. *Lupus* 2009; **18**: 1192–1197.

View | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

3 Gatto M, Agmon-Levin N, Soriano A, Manna R, Maoz-Segal R, Kivity S, Doria A, Shoenfeld Y: Human papillomavirus vaccine and systemic lupus erythematosus. *Clin Rheumatol* 2013. [epub ahead of print]. doi: 10.1007/s10067-013-2266-7.

View | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

4 Shoenfeld Y, Aharon-Maor A, Sherer Y: Vaccination as an additional player in the mosaic of autoimmunity. *Clin Exp Rheumatol* 2000; **18**: 181–184.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

5 Molina V, Shoenfeld Y: Infection, vaccines and other environmental triggers of autoimmunity. *Autoimmunity* 2005; **38**: 235–245.

View | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

6 Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y: Infections and autoimmunity—friends or foes? *Trends Immunol* 2009; **30**: 409–414.

[< Back](#)

7 Shoenfeld Y, Agmon-Levin N: 'ASIA' – Autoimmune/inflammatory syndrome induced by adjuvants. *J Autoimmun* 2011; **36**: 4–8.

View | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

8 Meroni PL: Autoimmune or auto-inflammatory syndrome induced by adjuvants (ASIA): old truths and a new syndrome? *J Autoimmun* 2010; **36**: 1–3.

View | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

9 Zafir Y, Agmon-Levin N, Paz Z, Shilton T, Shoenfeld Y: Autoimmunity following hepatitis B vaccine as part of the spectrum of 'Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants' (ASIA): analysis of 93 cases. *Lupus* 2012; **21**: 146–152.

View | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

10 Rosenblum H, Shoenfeld Y, Amital H: The common immunogenic etiology of chronic fatigue syndrome: from infections to vaccines via adjuvants to the ASIA syndrome. *Infect Dis Clin North Am* 2011; **25**: 851–863.

View | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

11 Lujan L, Perez M, Salazar E, Alvarez N, Gimeno M, Pinczowski P, Irusta S, Santamaria J, Insausti N, Cortes Y, Figueras L, Cuartielles I, Vila M, Fantova E, Chapulle JL: Autoimmune/autoinflammatory syndrome induced by adjuvants (ASIA syndrome) in commercial sheep. *Immunol Res* 2013; **56**: 317–324.

View | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

12 Katzav A, Kivity S, Blank M, Shoenfeld Y, Chapman J: Adjuvant immunization induces high levels of pathogenic antiphospholipid antibodies in genetically prone mice: another facet of the ASIA syndrome. *Lupus* 2012; **21**: 210–216.

View | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

13 Cerpa-Cruz S, Paredes-Casillas P, Landeros Navarro E, Bernard-Medina AG, Martinez-Bonilla G, Gutierrez-Urena S: Adverse events following immunization with vaccines containing adjuvants. *Immunol Res* 2013; **56**: 299–303.

View | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

[< Back](#)

View | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

15 Little DT, Ward HR: Premature ovarian failure 3 years after menarche in a 16-year-old girl following human papillomavirus vaccination. *BMJ Case Rep* 2012. [epub ahead of print]. doi: 10.1136/bcr-2012-006879.

View | [PubMed](#) | [Google Scholar](#)

16 Muechler EK, Huang KE, Schenk E: Autoimmunity in premature ovarian failure. *Int J Fertil* 1991; **36**: 99–103.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

17 Hoek A, Schoemaker J, Drexhage HA: Premature ovarian failure and ovarian autoimmunity. *Endocr Rev* 1997; **18**: 107–134.

View | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

18 Chattopadhyay D, Sen MR, Katiyar P, Pandey LK: Antiovarian antibody in premature ovarian failure. *Indian J Med Sci* 1999; **53**: 254–258.

[CAS](#) | [PubMed](#) | [Google Scholar](#)

19 Mande PV, Parikh FR, Hinduja I, Zaveri K, Vaidya R, Gajbhiye R, Khole VV: Identification and validation of candidate biomarkers involved in human ovarian autoimmunity. *Reprod Biomed Online* 2011; **23**: 471–483.

View | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

20 Kelkar RL, Meherji PK, Kadam SS, Gupta SK, Nandedkar TD: Circulating auto-antibodies against the zona pellucida and thyroid microsomal antigen in women with premature ovarian failure. *J Reprod Immunol* 2005; **66**: 53–67.

View | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

21 Poling JS, Frye RE, Shoffner J, Zimmerman AW: Developmental regression and mitochondrial dysfunction in a child with autism. *J Child Neurol* 2006; **21**: 170–172.

View | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

[< Back](#)

View | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

23 Cohen Tervaert JW, Kappel RM: Silicone implant incompatibility syndrome (SIIS): a frequent cause of ASIA (Shoenfeld's syndrome). *Immunol Res* 2013; **56**: 293–298.

View | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

24 Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y: Adjuvants and autoimmunity. *Lupus* 2009; **18**: 1217–1225.

View | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

25 Gherardi R, Authier F: Macrophagic myofasciitis: characterization and pathophysiology. *Lupus* 2012; **21**: 184–189.

View | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

26 Authier FJ, Sauvat S, Champey J, Drogou I, Coquet M, Gherardi RK: Chronic fatigue syndrome in patients with macrophagic myofasciitis. *Arthritis Rheum* 2003; **48**: 569–570.

 View | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

27 Israeli E, Pardo A: The sick building syndrome as a part of the autoimmune (auto-inflammatory) syndrome induced by adjuvants. *Mod Rheumatol* 2010; **21**: 235–239.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

28 Shoenfeld Y: HPV vaccines and autoimmune diseases. *J Intern Med* 2012; **272**: 98; author reply 99.

 View | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

29 Tomljenovic L, Shaw CA: No autoimmune safety signal after vaccination with quadrivalent HPV vaccine Gardasil? *J Intern Med* 2012; **272**: 514–515.

 View | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

30 Agmon-Levin N, Paz Z, Israeli E, Shoenfeld Y: Vaccines and autoimmunity. *Nat Rev Rheumatol* 2009; **5**: 648–652.

[< Back](#)

31 Israeli E, Agmon-Levin N, Blank M, Chapman J, Shoenfeld Y: Guillain-Barre syndrome—a classical autoimmune disease triggered by infection or vaccination. *Clin Rev Allergy Immunol* 2012; **42**: 121–130.

[View](#) | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

32 Ryan AM, Bermingham N, Harrington HJ, Keohane C: Atypical presentation of macrophagic myofasciitis 10 years post vaccination. *Neuromuscul Disord* 2006; **16**: 867–869.

[View](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

33 Poser CM, Behan PO: Late onset of Guillain-Barre syndrome. *J Neuroimmunol* 1982; **3**: 27–41.

[View](#) | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

34 Gherardi RK, Coquet M, Cherin P, Belec L, Moretto P, Dreyfus PA, Pellissier JF, Chariot P, Authier FJ: Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. *Brain* 2001; **124**(Pt 9): 1821–1831.

[View](#) | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

35 Couette M, Boisse MF, Maison P, Brugieres P, Cesaro P, Chevalier X, Gherardi RK, Bachoud-Levi AC, Authier FJ: Long-term persistence of vaccine-derived aluminum hydroxide is associated with chronic cognitive dysfunction. *J Inorg Biochem* 2009; **103**: 1571–1578.

[View](#) | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

36 Mikaeloff Y, Caridade G, Suissa S, Tardieu M: Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood. *Neurology* 2009; **72**: 873–880.

[View](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

37 Shivane A, Hilton DA, Moate RM, Bond PR, Endean A: Macrophagic myofasciitis: a report of second case from UK. *Neuropathol Appl Neurobiol* 2012; **38**: 734–736.

[View](#) | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

38 Lee SH: Detection of human papillomavirus L1 gene DNA fragments in postmortem blood and spleen after Gardasil® vaccination – a case report. *Adv Biosci Biotechnol* 2012; **3**: 1214–1224.

[< Back](#)

39 Lee SH: Detection of human papillomavirus (HPV) L1 gene DNA possibly bound to particulate aluminum adjuvant in the HPV vaccine Gardasil. *J Inorg Biochem* 2012; **112**: 85–92.

View | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#) |

40 Lee SH: Topological conformational changes of human papillomavirus (HPV) DNA bound to an insoluble aluminum salt-A study by low temperature PCR. *Adv Biol Chem* 2013; **3**: 76–85.

View | [CAS](#) | [Google Scholar](#) |

41 Souayah N, Michas-Martin PA, Nasar A, Krivitskaya N, Yacoub HA, Khan H, Qureshi AI: Guillain-Barre syndrome after Gardasil vaccination: data from Vaccine Adverse Event Reporting System 2006–2009. *Vaccine* 2011; **29**: 886–889.

View | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#) |

42 Sutton I, Lahoria R, Tan IL, Clouston P, Barnett MH: CNS demyelination and quadrivalent HPV vaccination. *Mult Scler* 2009; **15**: 116–119.

View | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#) |

43 Wildemann B, Jarius S, Hartmann M, Regula JU, Hametner C: Acute disseminated encephalomyelitis following vaccination against human papilloma virus. *Neurology* 2009; **72**: 2132–2133.

View | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#) |

44 Alvarez-Soria MJ, Hernandez-Gonzalez A, Carrasco-Garcia de Leon S, Del Real-Francia MA, Gallardo-Alcaniz MJ, Lopez-Gomez JL: [Demyelinating disease and vaccination of the human papillomavirus.]. *Rev Neurol* 2011; **52**: 472–476.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#) |

45 Das A, Chang D, Biankin AV, Merrett ND: Pancreatitis following human papillomavirus vaccination. *Med J Aust* 2008; **189**: 178.

 View | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#) |

46 Melo Gomes S, Glover M, Malone M, Brogan P: Vasculitis following HPV immunization. *Rheumatology (Oxford)* 2013; **52**: 581–582.

[< Back](#)

47 Pugnet G, Ysebaert L, Bagheri H, Montastruc JL, Laurent G: Immune thrombocytopenic purpura following human papillomavirus vaccination. *Vaccine* 2009; **27**: 3690.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

48 Della Corte C, Carlucci A, Francalanci P, Alisi A, Nobili V: Autoimmune hepatitis type 2 following anti-papillomavirus vaccination in a 11-year-old girl. *Vaccine* 2011; **29**: 4654–4656.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

49 Tomljenovic L, Shaw CA: Human papillomavirus (HPV) vaccine policy and evidence-based medicine: are they at odds? *Ann Med* 2013; **45**: 182–193.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

50 Tomljenovic L, Spinosa JP, Shaw CA: Human Papillomavirus (HPV) vaccines as an option for preventing cervical malignancies: (how) effective and safe? *Curr Pharm Des* 2013; **19**: 1466–1487.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

51 Chang J, Campagnolo D, Vollmer TL, Bompreszi R: Demyelinating disease and polyvalent human papilloma virus vaccination. *J Neurol Neurosurg Psychiatry* 2011; **82**: 1296–1298.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

52 Mendoza Plasencia Z, Gonzalez Lopez M, Fernandez Sanfiel ML, Muniz Montes JR: [Acute disseminated encephalomyelitis with tumefactive lesions after vaccination against human papillomavirus]. *Neurologia* 2010; **25**: 58–59.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

53 Schaffer V, Wimmer S, Rotaru I, Topakian R, Haring HP, Aichner FT: HPV vaccine: a cornerstone of female health a possible cause of ADEM? *J Neurol* 2008; **255**: 1818–1820.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

54 Tomljenovic L, Shaw CA: Too fast or not too fast: the FDA's approval of Merck's HPV vaccine gardasil. *J Law Med Ethics* 2012; **40**: 673–681.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

[< Back](#)[PubMed](#) | [Google Scholar](#)

56 Harper DM, Williams KB: Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies. *Discov Med* 2010; **10**: 7–17.

[PubMed](#) | [Google Scholar](#)

57 Schwarz TF: Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix. *Adv Ther* 2009; **26**: 983–998.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

58 Rinaldi M, Perricone R, Blank M, Perricone C, Shoenfeld Y: Anti-*Saccharomyces cerevisiae* autoantibodies in autoimmune diseases: from bread baking to autoimmunity. *Clin Rev Allergy Immunol* 2013. [epub ahead of print]. doi: 10.1007/s12016-012-8344-9

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

59 Chao C, Klein NP, Velicer CM, Sy LS, Slezak JM, Takhar H, Ackerson B, Cheetham TC, Hansen J, Deosaransingh K, Emery M, Liaw KL, Jacobsen SJ: Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. *J Intern Med* 2011; **271**: 193–203.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

60 Passeri E, Villa C, Couette M, Itti E, Brugieres P, Cesaro P, Gherardi RK, Bachoud-Levi AC, Authier FJ: Long-term follow-up of cognitive dysfunction in patients with aluminum hydroxide-induced macrophagic myofasciitis (MMF). *J Inorg Biochem* 2011; **105**: 1457–1463.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

61 Exley C: Aluminium-based adjuvants should not be used as placebos in clinical trials. *Vaccine* 2011; **29**: 9289.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

62 Gerhardus A, Razum O: A long story made too short: surrogate variables and the communication of HPV vaccine trial results. *J Epidemiol Community Health* 2010; **64**: 377–378.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

< Back

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

64 Tomljenovic L, Wilyman J, Vanamee E, Bark T, Shaw AC: HPV vaccines and cancer prevention, science versus activism. *Infect Agent Cancer* 2013; **8**: 6.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

Citing Literature



Citation Statements beta

Supporting 3	Mentioning 69	Contrasting 0
------------------------	-------------------------	-------------------------

Explore this article's citation statements on [scite.ai](#)

powered by **scite_**

[Download PDF](#)

ABOUT WILEY ONLINE LIBRARY

- [Privacy Policy](#)
- [Terms of Use](#)
- [About Cookies](#)
- [Manage Cookies](#)
- [Accessibility](#)

[Wiley Research DE&I Statement and Publishing Policies](#)
[Developing World Access](#)

HELP & SUPPORT

- [Contact Us](#)
- [Training and Support](#)
- [DMCA & Reporting Piracy](#)

OPPORTUNITIES

- [Subscription Agents](#)
- [Advertisers & Corporate Partners](#)

CONNECT WITH WILEY